Summary - Funding Rounds

Founding Date

1987

Total Funding

$29.5 m
In total, Repros Therapeutics had raised $29.5 m. Repros Therapeutics is a subsidiary of Allergan

Repros Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.0k3.0k9.0k9.0k11.0k47.0k

Revenue growth, %

22%(55%)

R&D expense

8.7m13.3m23.7m27.1m24.1m12.8m

General and administrative expense

3.8m4.8m4.8m5.4m5.1m4.6m

Operating expense total

12.5m18.2m28.5m32.5m29.2m17.3m

Depreciation and amortization

5.0k

EBIT

(12.5m)(18.2m)

EBIT margin, %

(624550%)(605567%)

Interest income

2.0k3.0k47.0k

Net Income

(12.5m)(18.2m)(27.7m)(32.5m)(29.2m)(17.3m)

Repros Therapeutics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

4.6m24.2m75.8m46.6m21.4m8.7m

Accounts Receivable

1.1m

Prepaid Expenses

99.0k406.0k189.0k289.0k84.0k

Current Assets

4.7m24.6m76.0m46.9m21.5m8.8m

PP&E

15.0k53.0k75.0k32.0k8.0k

Total Assets

6.1m26.8m79.0m46.9m21.5m8.8m

Accounts Payable

1.1m3.2m3.0m2.1m2.0m1.9m

Short-term debt

152.0k

Current Liabilities

1.4m3.8m3.6m2.9m2.9m2.7m

Total Debt

152.0k

Common Stock

12.0k17.0k23.0k24.0k24.0k

Preferred Stock

Additional Paid-in Capital

197.8m234.3m314.4m318.4m322.2m327.0m

Retained Earnings

(273.1m)(302.3m)(319.5m)

Total Equity

4.7m23.0m75.4m44.0m18.6m6.1m

Financial Leverage

1.3 x1.2 x1 x1.1 x1.2 x1.4 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

10.3m7.1m12.1m9.9m29.6m17.2m87.7m81.8m68.0m60.7m53.1m37.9m32.2m26.2m16.0m12.5m10.5m3.2m3.8m1.8m

Prepaid Expenses

198.0k188.0k298.0k245.0k451.0k355.0k304.0k193.0k583.0k383.0k264.0k569.0k438.0k311.0k293.0k250.0k158.0k304.0k268.0k135.0k

Current Assets

10.4m7.3m12.4m10.2m30.0m17.5m88.0m82.0m68.6m61.0m53.3m38.4m32.6m26.5m16.3m12.8m10.7m4.5m5.0m2.9m

PP&E

19.0k17.0k29.0k37.0k59.0k90.0k93.0k87.0k64.0k52.0k42.0k22.0k14.0k11.0k6.0k5.0k4.0k2.0k1.0k

Total Assets

11.7m8.6m14.0m11.9m32.0m19.9m90.6m84.8m71.8m64.3m56.8m38.5m32.6m26.5m16.3m12.8m10.7m5.4m5.9m3.8m

Accounts Payable

788.0k1.7m744.0k1.2m1.5m3.2m3.6m2.8m3.4m3.7m2.6m1.2m2.2m1.8m1.6m1.6m1.8m1.7m1.5m1.2m

Current Liabilities

1.7m2.0m909.0k1.4m1.8m3.6m3.9m3.2m3.9m4.1m3.0m2.0m2.9m2.5m2.1m2.3m2.3m2.8m2.7m2.4m

Total Liabilities

3.8m6.2m5.1m

Common Stock

12.0k12.0k15.0k15.0k17.0k19.0k23.0k23.0k23.0k23.0k24.0k24.0k24.0k24.0k24.0k24.0k25.0k27.0k33.0k40.0k

Preferred Stock

Additional Paid-in Capital

196.5m196.9m208.6m209.1m233.4m234.9m312.5m313.5m315.4m316.4m317.4m319.5m320.5m321.4m322.7m323.2m325.3m328.4m328.7m329.3m

Retained Earnings

(281.6m)(289.4m)(296.0m)(307.1m)(311.4m)(315.5m)(325.4m)(327.6m)(329.3m)

Total Equity

10.0m6.6m13.1m10.5m30.2m16.3m86.7m81.6m67.9m60.2m53.8m36.5m29.7m24.0m14.2m10.5m8.4m1.6m(309.0k)(1.3m)

Financial Leverage

1.2 x1.3 x1.1 x1.1 x1.1 x1.2 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.3 x3.3 x-19 x-2.9 x

Repros Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(12.5m)(18.2m)(27.7m)(32.5m)(29.2m)(17.3m)

Depreciation and Amortization

115.0k145.0k257.0k43.0k24.0k5.0k

Accounts Receivable

Inventories

Accounts Payable

100.0k2.0m(358.0k)(629.0k)(6.0k)(259.0k)

Cash From Operating Activities

(9.8m)(13.5m)(24.4m)(29.3m)(25.3m)(15.6m)

Purchases of PP&E

(15.0k)(30.0k)(63.0k)

Cash From Investing Activities

(335.0k)(608.0k)(911.0k)

Short-term Borrowings

Cash From Financing Activities

11.7m33.8m77.0m147.0k102.0k2.9m

Net Change in Cash

1.6m19.6m51.6m(29.2m)(25.2m)(12.7m)

Repros Therapeutics Ratios

USDQ2, 2011

Financial Leverage

1.2 x